BackMBX Biosciences Common Stock Overview

MBX Biosciences Common Stock Net Tangible Assets

Track MBX Biosciences Common Stock's net tangible assets ($410M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Net Tangible Assets
$409.54M
86.80% YoYΔ $190.30M vs prior year quarter

Peer average

Loading

MBX Biosciences Common Stock Net Tangible Assets History

Loading

MBX Biosciences Common Stock vs. peers: Net Tangible Assets Comparison

Loading

MBX Biosciences Common Stock Net Tangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

MBX Biosciences Common Stock (MBX) FAQ

MBX Biosciences Common Stock (MBX) currently reports a net tangible assets of $410M as of June 2026. That compares with $220M in the prior-year period — up 86.8% year over year. Use the charts on this page to explore MBX Biosciences Common Stock's net tangible assets history and peer comparisons.

MBX Biosciences Common Stock's net tangible assets increased from $220M to $410M — a 86.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

MBX Biosciences Common Stock reported $410M in net tangible assets as of June 2026. That compares with $220M in the prior-year period — up 86.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $410M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for MBX Biosciences Common Stock, and consider following MBX for alerts when major investors trade the stock.

MBX Biosciences Common Stock is classified in the Healthcare sector. On net tangible assets, it currently shows $410M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBX with unrelated industries.